159 related articles for article (PubMed ID: 37925171)
41. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
42. Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy.
Imai H; Kobayashi D; Kaira K; Kawashima S; Masubuchi K; Murata M; Ebara T; Kitamoto Y; Minato K
Radiol Oncol; 2022 Feb; 56(2):228-237. PubMed ID: 35218691
[TBL] [Abstract][Full Text] [Related]
43. Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival.
Ye Q; Hickey J; Summers K; Falatovich B; Gencheva M; Eubank TD; Ivanov AV; Guo NL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499305
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
46. Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate Oncogene Correlates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
Chen M; Li S; Liang Y; Zhang Y; Luo D; Wang W
Front Oncol; 2021; 11():656509. PubMed ID: 34178642
[TBL] [Abstract][Full Text] [Related]
47. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Takahashi T
Med Oncol; 2014 Aug; 31(8):88. PubMed ID: 24961467
[TBL] [Abstract][Full Text] [Related]
48. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
49. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
50. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhou Y; Chen H; Tang L; Feng Y; Tao Y; Huang L; Lou N; Shi Y
Immunotherapy; 2023 Feb; 15(3):209-220. PubMed ID: 36710655
[TBL] [Abstract][Full Text] [Related]
51. GALNT2, an O-glycosylating enzyme, is a critical regulator of radioresistance of non-small cell lung cancer: evidence from an integrated multi-omics analysis.
Dong X; Leng Y; Tian T; Hu Q; Chen S; Liu Y; Shen L
Cell Biol Toxicol; 2023 Dec; 39(6):3159-3174. PubMed ID: 37597090
[TBL] [Abstract][Full Text] [Related]
52. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
53. The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC.
Shen K; Wei Y; Lv T; Song Y; Jiang X; Lu Z; Zhan P; Wang X; Fan M; Lu W
BMC Bioinformatics; 2021 Sep; 22(1):471. PubMed ID: 34587898
[TBL] [Abstract][Full Text] [Related]
54. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
55. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
[TBL] [Abstract][Full Text] [Related]
56. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
Zhou X; Wang N; Zhang Y; Yu H; Wu Q
Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
[TBL] [Abstract][Full Text] [Related]
57. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Mei Y; Liu YB; Hu DL; Zhou HH
Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
[TBL] [Abstract][Full Text] [Related]
58. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
59. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
60. Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival.
Imai H; Onozato R; Kaira K; Kawashima S; Masubuchi K; Nagashima T; Tajima K; Minato K
Thorac Cancer; 2021 Oct; 12(20):2740-2748. PubMed ID: 34477313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]